Tobramycin eye drops
Function and Efficacy
This product belongs to the aminoglycoside antibiotics. The antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on Gram-negative bacteria such as Escherichia coli, aerogenes, Klebsiella, Proteus mirabilis, some indole-positive Proteus, Pseudomonas aeruginosa, some Neisseria, some non-pigmented Serratia and Shigella; the antibacterial effect of this product on Pseudomonas aeruginosa is 3 to 5 times stronger than that of gentamicin, and Pseudomonas aeruginosa that is moderately sensitive to gentamicin is highly sensitive to this product. Among Gram-positive bacteria, Staphylococcus aureus (including β-lactamase-producing strains) is sensitive to this product; Streptococci (including Streptococcus pyogenes, Pneumococcus, Streptococcus faecalis, etc.) are all resistant to this product. Anaerobic bacteria (Bacteroides), Mycobacterium tuberculosis, Rickettsia, viruses and fungi are also resistant to this product. The mechanism of action of this product is to bind to the 30S subunit of the bacterial ribosome and inhibit the synthesis of bacterial proteins.
Ingredients
Tobramycin
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| TobramycinIngredients |
This product belongs to the aminoglycoside antibiotics, which has antibacterial effects on Gram-negative bacteria such as Escherichia coli, aerogenes, Klebsiella, Proteus mirabilis, some indole-positive Proteus, Pseudomonas aeruginosa, some Neisseria, some non-pigmented Serratia and Shigella; the antibacterial effect on Pseudomonas aeruginosa is 3 to 5 times stronger than gentamicin. Among Gram-positive bacteria, Staphylococcus aureus (including β-lactamase-producing strains) is sensitive to this product; Streptococci (including Streptococcus pyogenes, Pneumococcus, Streptococcus faecalis, etc.) are resistant to this product. Anaerobic bacteria (Bacteroides), Mycobacterium tuberculosis, Rickettsia, viruses and fungi are also resistant to this product. The mechanism of action of this product is to bind to the 30S subunit of the bacterial ribosome and inhibit the synthesis of bacterial proteins. More |
32986-56-4 | 13 |
Appearance
This product is a colorless or almost colorless clear solution.
Indication
This product is suitable for local infections of the external eye and its appendages caused by sensitive bacteria.
Usage and Dosage
Drop into the eyelid. Mild and moderate infection: 1-2 drops at a time, once every 4 hours; severe infection: 2 drops at a time, once every hour.
Adverse Reactions
Occasionally, local irritation symptoms may occur, such as burning or swelling of the eyelids, conjunctival erythema, etc.; allergic reactions are rare.
Precautions
Patients who are allergic to this product or other aminoglycoside antibiotics are contraindicated.
Special Population Medication
Precautions for children: Because this product has potential nephrotoxicity and ototoxicity, it should be used with caution in children. Precautions for pregnancy and lactation: Pregnant women: Reproductive experiments on three animals using tobramycin at a dose 33 times that of human systemic medication did not show decreased fertility or fetal damage. However, there is currently no conclusive clinical research report on pregnant women, so pregnant women should only use this product when it is really necessary. Lactating women: Because of the potential for adverse reactions during breastfeeding, it is recommended to stop breastfeeding or stop taking the drug based on clinical considerations. Precautions for the elderly: Because this product has potential nephrotoxicity and ototoxicity, it should be used with caution in elderly patients.
Drug Interactions
1. This product combined with other aminoglycosides can increase ototoxicity, nephrotoxicity and neuromuscular blocking effects. Hearing loss may occur, and may still progress to deafness after discontinuation of the drug; hearing damage may recover or become permanent. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea), and anticholinesterase drugs or calcium salts can help restore the blocking effect. 2. This product combined with neuromuscular blocking drugs can aggravate neuromuscular blocking effects, leading to muscle weakness, respiratory depression or respiratory paralysis (apnea). Combined with plasma substitutes such as dextran, sodium alginate, diuretics such as ethacrynic acid, furosemide, capreomycin, cisplatin, vancomycin, etc., or continuous local or systemic application, can increase ototoxicity and nephrotoxicity, hearing damage may occur, and may still develop to deafness after discontinuation of the drug, and hearing damage may recover or become permanent. 3. This product combined with ceftriaxone may increase nephrotoxicity. 4. This product combined with polymyxins can increase nephrotoxicity and neuromuscular blocking effects. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea). 5. This product should not be used in combination with other nephrotoxic or ototoxic drugs or used sequentially to avoid nephrotoxicity or ototoxicity.
Storage
Keep away from light and store in a sealed container.
Packaging Specification
0.3%
Validity Period
24 months
Manufacturer
Nanjing Tianlang Pharmaceutical Co., Ltd.
-
Founded in:
2005-03-17 -
Address:
South District of Economic Development Zone, Lishui District, Nanjing (Yongyang Town) -
Tax NO.:
91320117771266683G -
Registered Funds:
8 million yuan -
Website:
-
Email: